Knight Therapeutics Inc. has seen a modest uptick in its stock performance over the past week, driven by recent regulatory approvals and product launches.
Knight Therapeutics Inc. (GUD.TO) experienced a slight decline of 0.68% in its stock price on Tuesday, but the overall weekly performance shows a gain of 1.60%. The company's recent announcements regarding regulatory approvals and product launches have positioned it positively in the market, contributing to a year-to-date increase of 72.25%.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$1.01B
P/E
68.3x
52W high
$10.34
52W low
$5.66
1W change
+1.60%
Beta
0.04
Analyst Price Targets
Based on analyst covering GUD · as of Sep 17, 2026
Wall Street analysts forecast GUD stock price to rise 9.9% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+9.9% Upside
Current Price
C$10.18
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
29.4%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
+35.7%
Annualized drift
90d Mean
C$11.57
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.62 | C$9.60 – C$11.76 |
| 60 trading days | C$11.08 | C$9.60 – C$12.79 |
| 90 trading days | C$11.57 | C$9.70 – C$13.79 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Knight Therapeutics has achieved significant gains this year, investors should keep an eye on upcoming regulatory developments and financial performance to assess future growth potential.
Knight Therapeutics Reports 503% Increase in Q1 Net Income
The company reported a significant rise in net income for Q1 2026, raising its revenue guidance, which may bolster investor confidence.
Bull case
The recent regulatory approvals for TAVALISSE® in Colombia and the launch of WYNZORA® in Canada could boost revenue streams, supporting the positive outlook from analysts.
Bear case
Despite these positive developments, the high P/E ratio of 68.33 suggests that the stock may be overvalued relative to its earnings, which could be a concern for potential investors.
Recent Company Developments
Knight Therapeutics has made headlines recently with several important announcements. The company received regulatory approval from INVIMA in Colombia for TAVALISSE®, a drug aimed at treating chronic immune thrombocytopenia in adults. Additionally, they submitted a supplemental New Drug Submission for MINJUVI® in Brazil for patients with relapsed or refractory diffuse large B-cell lymphoma. Moreover, Knight launched WYNZORA®, a topical corticosteroid for plaque psoriasis, in Canada. These developments reflect the company's active role in expanding its product offerings and addressing critical health needs.
Advertisement
Technical Picture
As of the latest trading session, Knight Therapeutics' stock closed at C$10.28. The stock is currently trading above its 50-day moving average of C$9.73, indicating a positive short-term trend. The 200-day moving average stands at C$7.80, suggesting robust long-term performance. The stock's 52-week range has been between C$5.66 and C$10.34, showing that it has traded within 99% of its range. With a beta of 0.04, the stock exhibits low volatility compared to the market, which may appeal to risk-averse investors. The trading volume was 120,912 shares, which is below the 20-day average volume of 84,817 shares, indicating reduced trading activity.
Insider Activity
No insider trading activity has been reported recently for Knight Therapeutics, suggesting stability in the management and ownership structure.
Price Action and Market Outlook
Despite the minor decline of 0.68% today, Knight Therapeutics has shown solid performance over the past week with a 1.60% gain. The stock's year-to-date performance is impressive at 72.25%, indicating strong investor interest and confidence in the company's growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
